MeSH term
Frequency | Condition_Probility | Adult | 20 | 0.0 |
Alleles | 4 | 0.0 |
Bipolar Disorder/enzymology/*genetics | 3 | 25.0 |
Dopa Decarboxylase/*genetics | 16 | 94.0 |
Gene Frequency | 4 | 0.0 |
Genotype | 6 | 0.0 |
Humans | 91 | 0.0 |
Middle Aged | 18 | 0.0 |
Research Support, Non-U.S. Gov't | 50 | 0.0 |
Sequence Deletion | 4 | 0.0 |
Adolescent | 3 | 0.0 |
Child | 3 | 0.0 |
Child, Preschool | 4 | 0.0 |
Female | 29 | 0.0 |
Haplotypes | 2 | 0.0 |
Male | 34 | 0.0 |
Enzyme Inhibitors/pharmacology | 2 | 0.0 |
Aged | 8 | 0.0 |
Catechol O-Methyltransferase/*antagonists & inhibitors/metabolism | 2 | 33.0 |
Cross-Over Studies | 2 | 0.0 |
Dopamine/metabolism | 3 | 2.0 |
Enzyme Inhibitors/*pharmacology | 2 | 0.0 |
Tomography, Emission-Computed | 4 | 3.0 |
Drug Administration Schedule | 2 | 0.0 |
Drug Therapy, Combination | 9 | 0.0 |
HIV Infections/*drug therapy | 3 | 1.0 |
*HIV-1 | 3 | 0.0 |
Pilot Projects | 2 | 0.0 |
RNA, Viral | 2 | 4.0 |
Treatment Outcome | 4 | 0.0 |
Viral Load | 3 | 0.0 |
Acquired Immunodeficiency Syndrome/*drug therapy | 2 | 3.0 |
Microscopy, Electron | 2 | 0.0 |
Animals | 19 | 0.0 |
Binding Sites | 2 | 0.0 |
Kidney/enzymology | 2 | 1.0 |
Models, Molecular | 2 | 0.0 |
Protein Structure, Secondary | 2 | 0.0 |
Brain/*enzymology | 2 | 1.0 |
Genetic Predisposition to Disease | 2 | 0.0 |
Catechol O-Methyltransferase/*antagonists & inhibitors | 2 | 7.0 |
Levodopa/therapeutic use | 2 | 7.0 |
Cells, Cultured | 6 | 0.0 |
Comparative Study | 18 | 0.0 |
Reproducibility of Results | 2 | 0.0 |
Dopa Decarboxylase/*analysis/*biosynthesis | 2 | 100.0 |
Flow Cytometry | 2 | 0.0 |
Infant | 4 | 0.0 |
RNA, Messenger/analysis | 2 | 0.0 |
Tumor Markers, Biological/*analysis | 2 | 0.0 |
*Polymorphism, Genetic | 3 | 0.0 |
Antiviral Agents/*pharmacology | 4 | 2.0 |
Dideoxynucleosides/*pharmacology | 4 | 50.0 |
Reverse Transcriptase Inhibitors/*pharmacology | 4 | 30.0 |
Tumor Cells, Cultured | 7 | 0.0 |
Base Sequence | 10 | 0.0 |
DNA Primers | 3 | 0.0 |
Reference Values | 3 | 0.0 |
Double-Blind Method | 3 | 0.0 |
HIV-1/*drug effects/physiology | 3 | 3.0 |
Reverse Transcriptase Inhibitors/*pharmacology/therapeutic use | 3 | 33.0 |
Virus Replication/drug effects | 4 | 1.0 |
Zidovudine/pharmacology/therapeutic use | 2 | 20.0 |
English Abstract | 2 | 0.0 |
Polymerase Chain Reaction | 6 | 0.0 |
Survival Analysis | 3 | 0.0 |
Denmark | 2 | 1.0 |
Family Health | 2 | 0.0 |
Anti-HIV Agents/*pharmacology | 6 | 4.0 |
Cell Division/drug effects | 4 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 19 | 0.0 |
CD4 Lymphocyte Count | 3 | 0.0 |
*Mutation | 2 | 0.0 |
Dopa Decarboxylase/*metabolism | 7 | 87.0 |
Kinetics | 8 | 0.0 |
Time Factors | 6 | 0.0 |
Tyrosine 3-Monooxygenase/*metabolism | 3 | 3.0 |
Drug Interactions | 6 | 0.0 |
Cholesterol/blood | 2 | 0.0 |
DNA Probes | 3 | 0.0 |
Sensitivity and Specificity | 5 | 0.0 |
Triglycerides/blood | 2 | 0.0 |
*Viral Load | 2 | 1.0 |
Anti-HIV Agents/*therapeutic use | 2 | 0.0 |
Zidovudine/*therapeutic use | 2 | 1.0 |
Blotting, Western | 3 | 0.0 |
Cloning, Molecular | 5 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 2 | 0.0 |
Cell Line | 6 | 0.0 |
Drug Synergism | 3 | 0.0 |
HIV-1/*drug effects | 3 | 2.0 |
Dideoxynucleosides/*therapeutic use | 2 | 14.0 |
Disease Progression | 2 | 0.0 |
Follow-Up Studies | 2 | 0.0 |
HIV Infections/*drug therapy/mortality | 2 | 7.0 |
Amino Acid Sequence | 5 | 0.0 |
Molecular Sequence Data | 8 | 0.0 |
Sequence Homology, Amino Acid | 2 | 0.0 |
Virus Replication/*drug effects | 3 | 1.0 |
Virus Replication | 2 | 0.0 |
Anti-HIV Agents/*adverse effects/therapeutic use | 2 | 9.0 |
Quality Control | 2 | 1.0 |
Drug Carriers | 4 | 3.0 |
Immunohistochemistry | 2 | 0.0 |
Mice | 8 | 0.0 |
Fluorine Radioisotopes/*diagnostic use | 2 | 16.0 |
Image Processing, Computer-Assisted | 2 | 0.0 |
Models, Biological | 3 | 0.0 |
Tomography, Emission-Computed/*methods | 2 | 8.0 |
Dihydroxyphenylalanine/*metabolism | 2 | 66.0 |
Antineoplastic Agents/pharmacology | 2 | 0.0 |
Mice, Nude | 2 | 0.0 |
Neoplasm Transplantation | 2 | 0.0 |
Zalcitabine/*pharmacology | 3 | 50.0 |
Antiviral Agents/*therapeutic use | 2 | 1.0 |
Half-Life | 3 | 0.0 |
Microbial Sensitivity Tests | 2 | 0.0 |
Structure-Activity Relationship | 3 | 0.0 |
Substrate Specificity | 3 | 0.0 |
Biological Transport | 2 | 0.0 |
Fluorine Radioisotopes/diagnostic use | 2 | 20.0 |
HIV-1 Reverse Transcriptase | 3 | 4.0 |
Pregnancy | 2 | 0.0 |
Chromosome Mapping | 3 | 0.0 |
*Chromosomes, Human, Pair 7 | 3 | 1.0 |
Genetic Markers | 2 | 0.0 |
Pedigree | 2 | 0.0 |
Immunoblotting | 2 | 0.0 |
Dopa Decarboxylase/metabolism | 2 | 40.0 |
Tyrosine 3-Monooxygenase/metabolism | 2 | 1.0 |
HIV/*drug effects | 2 | 8.0 |
Liposomes | 3 | 1.0 |
Rats | 4 | 0.0 |
Tissue Distribution | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 2 | 0.0 |
Zidovudine/pharmacology | 2 | 3.0 |
Zidovudine/*pharmacology | 3 | 11.0 |
Hydrogen-Ion Concentration | 2 | 0.0 |
Liver/*enzymology | 2 | 0.0 |
Species Specificity | 2 | 0.0 |
Neurons/metabolism | 2 | 0.0 |
*Chromosome Mapping | 2 | 0.0 |
Cell Survival/drug effects | 2 | 0.0 |
Aromatic-L-Amino-Acid Decarboxylases/*genetics | 2 | 22.0 |
*Genes, Structural | 2 | 0.0 |
Restriction Mapping | 2 | 0.0 |
Dose-Response Relationship, Drug | 2 | 0.0 |
Clinical Trials | 2 | 0.0 |
Organ Specificity | 2 | 0.0 |
Oxidation-Reduction | 2 | 0.0 |
Molecular Weight | 2 | 0.0 |
In Vitro | 2 | 0.0 |
Drug Tolerance | 2 | 1.0 |
Drug Evaluation | 2 | 0.0 |
Blotting, Northern | 2 | 0.0 |
Dopamine beta-Hydroxylase/*metabolism | 2 | 9.0 |
Phenylethanolamine N-Methyltransferase/*metabolism | 2 | 14.0 |
